Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate RiskAccesswire • 07/04/22
FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivirPRNewsWire • 07/01/22
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics, and BeyondPRNewsWire • 06/23/22
Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for AviptadilAccesswire • 06/13/22
NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation (BTD) Request for ZYESAMI® (aviptadil)PRNewsWire • 06/11/22
NRx Pharmaceuticals Appoints Seth Van Voorhees, PhD, as Chief Financial Officer and TreasurerPRNewsWire • 06/08/22
Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19Accesswire • 05/26/22
NRx Pharmaceuticals Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19PRNewsWire • 05/26/22
NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. Global Investment ConferencePRNewsWire • 05/19/22
NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/16/22
NRx Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial ResultsPRNewsWire • 05/16/22
NRx Pharmaceuticals Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute SuicidalityPRNewsWire • 05/12/22
NRX PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of NRx Pharmaceuticals, Inc. - NRXPBusiness Wire • 05/05/22
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for AviptadilAccesswire • 04/22/22
NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 TherapyBenzinga • 04/21/22
NRx Pharmaceuticals Files New Breakthrough Therapy Designation Request for ZYESAMI® (aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure that were also treated with Remdesivir and continued to progressPRNewsWire • 04/21/22
NRx Pharmaceuticals' Interim CEO and other Leaders to Present at 21st Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/08/22
NRx Pharmaceuticals, Inc. (NRXP) CEO Robert Besthof on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/31/22
NRx Pharmaceuticals Provides Business Update and Reports Full Year 2021 Financial ResultsPRNewsWire • 03/31/22
